FOI release

The number of patients currently receiving each long-term prophylactic medicine

This request was refused in part, so we didn't provide some of the information the requester asked for. This may include information where we can neither confirm nor deny that we hold it.

Case reference FOI2026/02327

Received 8 June 2026

Published 10 September 2026

Request

  1. The number of patients currently receiving each long-term prophylactic medicine — lanadelumab, berotralstat, garadacimab, plasma-derived C1-esterase inhibitor (Cinryze and/or Haegarda) — as at the most recent month available.

  2. The same counts for each month/quarter from January 2023 onward, if readily held.

  3. A breakdown of the current counts by patients' ICB of residence (or first half of postcode / "out-of-area vs in-area"), to whatever level your systems allow without identifying individuals.

    For lanadelumab specifically, the split between every-2-week and every-4-week dosing among current patients, if recorded.

Response

1. The number of patients currently receiving each long-term prophylactic medicine — lanadelumab, berotralstat, garadacimab, plasma-derived C1-esterase inhibitor (Cinryze and/or Haegarda) — as at the most recent month available.  

36

2. The same counts for each month/quarter from January 2023 onward, if readily held.  

Data not held

3. A breakdown of the current counts by patients' ICB of residence (or first half of postcode / "out-of-area vs in-area"), to whatever level your systems allow without identifying individuals.

Postcode

Count of pat

GU34

<5

MK18

<5

NN13

<5

NN16

<5

NN2

<5

OX12

<5

OX13

<5

OX14

<5

OX15

<5

OX16

<5

OX17

<5

OX18

<5

OX2

<5

OX26

<5

OX28

<5

OX29

<5

OX4

<5

OX6

<5

OX7

<5

RG18

<5

SL2

<5

SN11

<5

SN7

<5

SP1

<5

TA1

<5

Grand Total

32

 

Please note: All values given as <5 are done so to prevent this data from being person identifiable. This is done under section 40 (2) of the FOIA. 


For lanadelumab specifically, the split between every-2-week and every-4-week dosing among current patients, if recorded.  

Data not held


Documents

There are no documents for this release.

This is Oxford University Hospitals NHS Foundation Trust's response to a freedom of information (FOI) or environmental information regulations (EIR) request.

You can browse our other responses or make a new FOI request.